The Winner Of The Pharma Battle Royale

Apr. 18, 2013 9:16 PM ETCVS, WBA
Activist Stocks profile picture
Activist Stocks's Blog
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Long/Short Equity, Deep Value, Special Situations, Growth

Contributor Since 2012

At Activist Stocks we use hedge funds and activist investors to find actionable investing ideas. That is, stocks with catalysts to unlock and generate shareholder value. Activist Stocks also offers a catalyst and event-driven idea forum for investors looking for unique idea generation, Catalyst-Driven Small-Caps, where I share daily activist and turnaround insights and deep dives. 

Be sure to check out our detailed stock analysis (click here). CVS Caremark (NYSE: CVS) and Walgreen (NYSE: WAG) are the two leaders in the pharma industry, however, the questions is, which is the better investment? A quick look at the valuation and the continued success of CVS' market share gains could mean that CVS is your best bet in the pharma industry.

Top pick

CVS is the largest provider of prescription and related health care services in the U.S. The company has three segments, pharmacy services, retail pharmacy, and corporate. Its pharmacy services business provides a full range of prescription benefit management (PBM) services, including mail order pharmacy services, specialty, and plan design and administration.

CVS' retail segment continued its growth last quarter, with revenue increasing 5% on the back of a 4% growth in same-store sales. This was in part triggered by the benefit from market gains due to the Express Scripts-Walgreen contract fallout. As for its other initiative, MinuteClinics, the segment posted impressive growth last quarter, up 38% year over year and adding 31 new clinics during the quarter.


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.